Montreux, Switzerland / Montpellier, France | November 2, 2022 – CYTEA|BIO, a preclinical-stage biotechnology company focusing on allogeneic cellular immunotherapies combining non genetically modified effector cells (such as NK cells and macrophages) with targeting ligands, announced today that the company has been invited to attend the upcoming Jefferies Healthcare Conference. The conference will be held in London from November 15-17, 2022.
The Jefferies Healthcare Conference is the largest healthcare-dedicated investor conference in Europe covering pharma, biotech, medtech and healthcare services. The past conference saw 550 companies and 3,000 attendees from Americas, Europe, Middle East, Africa, and Asia join the event.
The conference features leading public companies and private companies at different stages of preparation for an IPO and/or companies that are looking for partnering and other business development opportunities.
For more information please contact: